Sun Pharma Q1FY18

1. Sales / Income from operations at Rs. 6,167 cr, de-growth of 23% (Y-O-Y)
2. India sales at Rs. 1,761 cr, down by 5% over Q1 (Y-O-Y).
3. US finished dosage sales at US$ 351 million down by 42% over Q1 (Y-O-Y). 
4. US sales for Q1 last included the benefit of the 180-day exclusivity for Imatinib which expired in July-2016.
5. Emerging Markets sales at US$ 168 million up by 9% over (Y-O-Y).
6. Rest of World sales at US$ 115 million, growth of 37% over Q1 l(Y-O-Y).
7. R&D investments at Rs. 522 cr (8.5% of sales) compared to Rs. 531 cr (6.6% of sales) for Q1FY17.
8. EBITDA at Rs. 1,054 crs, resulting EBITDA margin of 17.1%.
9. Net profit for the quarter was adversely impacted by settlements with certain plaintiffs related to the Modafinil  antitrust litigation in the US, with the settlement amounting to Rs 950 cr. Excluding the Modafinilsettlement
10. Adjusted net profit for Q1FY18 was at Rs. 526 cr, down 74% over Q1 last year, withresulting adjusted net profit margin of 8.5%.